CV

Abstract

I have a long-standing interest in investigating cellular behaviors and interactions in complex environments. My PhD studies in the Joyce Lab focused on uncovering the transcriptional regulation and developmental ontogeny of tumor-associated macrophages in brain tumors. I employed computational tools and a number of different genetic lineage tracing and tumor models with complementary analysis on patient-derived specimen. As I studied the functions of myeloid cells in disease, I became increasingly interested in the epigenetic mechanisms regulating their development, and how these processes can be co-opted in leukemia.

In the fall of 2016, I began my postdoctoral work with Dr. Ross Levine, setting out to model clonal evolution and clone-clone interactions in myeloid leukemias. In a recently published co-first author study in Nature, I developed an analytical framework for the analysis of single cell DNA sequencing, resulting in a comprehensive understanding of the genetic architecture of myeloid malignancy. I further developed a series of novel murine genetic tools to evaluate mutation order and oncogene-dependency using multiple, orthogonally inducible recombinases. These studies have revealed distinct patterns disease penetrance and immunophenotype depending upon the cooperating mutations.

Education

Positions and Employment

Publications

Full list of publications can be found here

Fellowships and Honors

Other Experience and Professional Memberships

Presentations and Seminars

Patents

1. Compositions and methods for treatment of glioma (PCT/US2016/031431). Daniela F Quail, Johanna A Joyce, Robert L Bowman. This patent covers the dual targeting of CSF-1R inhibition and PI3-Kinase inhibition, or IGF-1R inhibitors, in the treatment of glioblastoma multiforme and other brain malignancies. The rationale is that CSF-1R targeting results in altered tumor associated macrophage function which engenders a dependency in tumor cells upon macrophage-derived IGF1 for survival. November 17th, 2016
2. Inhibition of colony stimulating factor-1 receptor signaling for the treatment of brain cancer (PCT/US2013/036628). Johanna A Joyce, Robert L Bowman. This patent covers the utility of a gene expression signature in predicting responsiveness to CSF-1R inhibitor therapy in glioblastoma multiforme and other brain malignancies. October 24th, 2013

Research Grants

1. PI: K99CA248460-01, NIH Pathway to Independence Award (Parent K99/R00). Interrogating oncogene-dependency and mutation order in FLT3 mutant AML. 04/01/20-03/31/22
2. Co-I: R01CA237213, NCI. Mechanisms of UV-mediated melanoma development. 09/04/202-05/31/2025. ($84,745 of $1,774,506)
3. PI: DR-SG 22-17, Damon Runyon-Sohn Cancer Research Foundation. Interrogating subclonal architecture and functional contributions of mutation order in AML. 07/01/17-03/31/20
4. PI: F31 CA167863-01-04. NCI. The Roles of Microglia and Macrophage Populations in the Glioma Microenvironment. 09/18/12–09/17/16

Scientific Leadership and Teaching